Drug companion protocol
NAD+
A cellular redox coenzyme involved in energy metabolism, DNA repair, and mitochondrial function; injectable protocols are typically compounded or research-context references.
Quickstart Highlights
- Drug class
- Cellular coenzyme
- Route
- Subcutaneous injection
- Schedule
- Editorial research protocol reference describes daily subcutaneous titration from a 500 mg vial; no approved subcutaneous therapeutic dosing label exists
- Evidence score
- 30
Quickstart highlights
- 💉Subcutaneous injection
- 🔬Cellular coenzyme
- 🧪Lyophilised powder — requires reconstitution with bacteriostatic water
How this works
Mechanism of action and pharmacokinetic profile from published data.
NAD+ is a nicotinamide-derived coenzyme central to redox metabolism, mitochondrial energy production, and DNA repair signaling. Clinical literature more commonly describes intravenous NAD+ exposure, while subcutaneous maintenance-style protocols are editorial or compounded references.
- Time to peak (Tmax)
- Not established for the subcutaneous editorial protocol.
- Clearance
- NAD+ is consumed and recycled through cellular metabolic pathways.
- Elimination half-life
- Not applicable as a simple peptide-like exposure metric for this editorial compounded protocol.
- Bioavailability
- Published clinical use is often intravenous; subcutaneous protocol references are not equivalent to an approved label.
Dosing & Reconstitution Guide
Full preparation, protocol, and administration reference for compounded lyophilised formulations.
Protocol overview
Editorial research protocol reference describes daily subcutaneous titration from a 500 mg vial; no approved subcutaneous therapeutic dosing label exists.
Dose escalation phases
Editorial NAD+ 500 mg vial titration reference
| Phase | Dose | Frequency | Guidance |
|---|---|---|---|
| Week 1 Week 1-1 | 50 mg | once daily | Editorial tolerance reference. Not approved dosing. Use clinician or compounder instructions when applicable. |
| Week 2 Week 2-2 | 75 mg | once daily | Editorial titration reference. Do not escalate based on this table as medical advice. |
| Weeks 3-16 Week 3-16 | 100 mg | once daily | Editorial maintenance-style reference. No approved maintenance duration exists for this compounded protocol. |
Supplies needed
- ◦Research or compounded vial and diluent — Use the vial size and bacteriostatic water volume described by the applicable protocol or compounder. NAD+ solution should be inspected for clarity.
Editorial 500 mg vial titration (166.7 mg/mL)
| Phase / Dose | U-100 Units | Volume (mL) |
|---|---|---|
| Week 1 | 30 | 0.30 |
| Week 2 | 45 | 0.45 |
| Weeks 3-16 reference | 60 | 0.60 |
Reconstitution steps
Vial size
500 mg
BAC water to add
3 mL
Resulting concentration
166.7 mg/mL
At about 166.7 mg/mL, 1 U-100 unit = 0.01 mL = about 1.67 mg NAD+. Example editorial conversions: 50 mg = 30 units, 75 mg = 45 units, 100 mg = 60 units.
Editorial protocol: allow vial to reach room temperature, add 3.0 mL bacteriostatic water slowly down the vial wall, do not shake vigorously, swirl or roll until clear and colorless, label, protect from light, and refrigerate.
Injection steps
- 1Protect from light
After reconstitution, label with date and concentration, refrigerate, protect from light, and discard if cloudy, discolored, or particulate.
Storage instructions
Before reconstitution
Editorial protocol describes frozen lyophilized storage around -20 C or below, dry and protected from light.
After reconstitution
Refrigerate reconstituted solution at 2-8 C, protect from light, and inspect for clarity.
Editorial page describes up to 14 days.
Important notes
- !Compounded protocol limitation
This guide is not an approved subcutaneous NAD+ product label.
Concentration calculations are standard compounding arithmetic. Protocol phases are drawn from published Phase 2 trial data. Your prescriber and dispensing pharmacy determine the actual dose, vial size, and escalation schedule for your treatment.
Your journey
Where you are in a typical protocol, and what one dose cycle looks like. Educational — your prescriber tailors the plan to you.
Protocol timeline
Starter reference
Weeks 1–150 mgevery 1dWhat to expect: editorial low-start tolerance reference
Focus on: track sleep/anxiety/fatigue symptoms, inspect solution clarity
Common adjustments: no approved adjustment rules exist
Step-up reference
Weeks 2–275 mgevery 1dWhat to expect: editorial intermediate titration reference
Focus on: document tolerance, site rotation
Common adjustments: pause escalation if concerning symptoms occur
Maintenance-style reference
Weeks 3–16100 mgevery 1dWhat to expect: editorial 100 mg/day reference
Focus on: protect from light, monitor injection-site response
Common adjustments: no approved duration rule exists
Daily companion
Practical playbooks for managing symptoms, eating around side effects, tracking what matters, and reporting back to your clinician.
Food guidance by situation
Prefer: morning routine if sleep disruption occurs, steady hydration
Limit: late-day dosing if it disrupts sleep
Avoid: unsupported protocol stacking
The source notes tolerability concerns such as insomnia, anxiety, or fatigue at higher starting doses.
What to track
Suggested check-in cadence: daily.
Injection-site reaction
scale 0 10
Energy
scale 0 10
Sleep quality
scale 0 10
Unexpected symptoms
text
Safety and interactions
Share this information with your prescriber for personalised care decisions.
Red-flag symptoms — seek urgent care
- Severe systemic symptomsUrgent careSeek urgent care for chest symptoms, fainting, breathing symptoms, swelling, or severe allergic symptoms after injectable NAD+.
- Unexpected systemic reaction. Seek medical advice for severe injection-site reaction, rash, swelling, breathing symptoms, severe anxiety, chest symptoms, fainting, or other concerning symptoms.
Structured warnings
Compounded protocol, not an approved label
Subcutaneous NAD+ protocol dosing is represented here as an editorial compounded/research reference. It is not an approved product label.
Unexpected systemic reaction
Seek medical advice for severe injection-site reaction, rash, swelling, breathing symptoms, severe anxiety, chest symptoms, fainting, or other concerning symptoms.
Indication and approval status
No approved subcutaneous therapeutic dosing indication represented in this catalogue entry.
No approved prescribing population for the editorial subcutaneous protocol.
Who should not take this
No approved subcutaneous NAD+ therapeutic dosing label is represented in this catalogue entry. Formal contraindications, dose adjustments, and monitoring requirements depend on the actual compounded product and clinical context.
Missed-dose guidance
No approved missed-dose rule exists for this subcutaneous NAD+ protocol.
Do not double doses based on an editorial schedule; discuss interruptions with a clinician or compounder.
When to seek help
Severe anxiety, insomnia, fatigue, chest symptoms, fainting, allergic symptoms, or severe injection-site reaction after subcutaneous NAD+.
Stop use and contact a clinician; urgent care for chest symptoms, fainting, breathing symptoms, or swelling.
Approved injection sites
Abdomen
Rotate sites daily and stay at least 2 inches from the navel.
Avoid: Avoid bruised, red, hard, scarred, or irritated skin.
Thigh
Rotate between abdomen and outer thigh areas.
Avoid: Avoid tender, bruised, red, or hardened skin.
Structured storage
research lyophilized vial
before reconstitution
-20 C or below
Editorial protocol emphasizes dry, dark storage because NAD+ powder is hygroscopic.
research reconstituted vial
after reconstitution
2-8 C
Editorial page describes up to 14 days.
Inspect before each use; discard if cloudy, discolored, or particulate.
Storage and handling
NAD+ is hygroscopic and light sensitive. Editorial protocol pages describe frozen lyophilized storage and refrigerated, light-protected storage after reconstitution; those instructions are not an approved product label.
Research evidence
Published studies, labels, regulator pages, and curated protocol sources connected to this profile.
API source references
NAD+ 500 mg vial PeptideDosages protocol
Editorial research protocol page for NAD+ 500 mg vial; not a prescribing label.
Open source ↗Get the full companion experience in Viora
Week-by-week reminders, food and symptom tracking, and the complete companion guide in one place.
Available on iOS and Android.